HM1 Chief Executive Officer, Paul Rayson appeared on AusBiz to discuss the Hearts and Minds model, our outstanding FY20 results, the increased need for mental health funding and the upcoming Sohn Hearts & Minds Conference. Watch the interview below:
CEO Paul Rayson says HM1's results are outstanding given the bumpy period. COVID-19 has shone a light on medical research and he's proud to contribute to the field and help support people during these tough times.
CEO Paul Rayson says HM1's results are outstanding given the bumpy period. COVID-19 has shone a light on medical research and he's proud to contribute to the field and help support people during these tough times.Read Transcript
HM1 Chief Executive Officer, Paul Rayson appeared on AusBiz to discuss the Hearts and Minds model, our outstanding FY20 results, the increased need for mental health funding and the upcoming Sohn Hearts & Minds Conference. Watch the interview below:
We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.
We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.
We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.
We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.
We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.
Listen to episode one with Chief Investment Officer Charlie Lanchester and TDM Growth Partners Investment Team Members Ed Cowan and Fraser Christie. They share their unique investment philosophies and delve into two high conviction stocks recommended for the HM1 portfolio.